Roche Klonopin anti-generic campaign includes letters to physicians, journal ads for perforated tabs.
GENERIC CLONAZEPAM DOES NOT MEET KLONOPIN DISSOLUTION STANDARDS, ROCHE CLAIMS in a recent mailing to physicians and pharmacists. "Our tests of the Teva Pharmaceuticals brand of clonazepam tablets indicate that some batches of the product do not meet the dissolution standards that the FDA requires Klonopin tablets to meet," the cover letter asserts. Roche adds that "we have no evidence that the Teva product is not bioequivalent to Klonopin, but the disparity in dissolution standards is, in our view, unwarranted."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth